Compare · DXCM vs PDEX
DXCM vs PDEX
Side-by-side comparison of DexCom Inc. (DXCM) and Pro-Dex Inc. (PDEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PDEX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 170.6x PDEX ($194.1M).
- Over the past year, DXCM is up 25.7% and PDEX is up 136.8% - PDEX leads by 111.0 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 2 for PDEX).
- DXCM has more recent analyst coverage (25 ratings vs 0 for PDEX).
- Company
- DexCom Inc.
- Pro-Dex Inc.
- Price
- $86.05-1.93%
- $61.58-1.69%
- Market cap
- $33.10B
- $194.1M
- 1M return
- -2.13%
- -13.35%
- 1Y return
- +25.75%
- +136.75%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Pro-Dex Inc.
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest PDEX
- SEC Form DEFA14A filed by Pro-Dex Inc.
- SEC Form DEF 14A filed by Pro-Dex Inc.
- Pro-Dex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Chief Executive Officer Van Kirk Richard Lee Jr sold $45,412 worth of shares (765 units at $59.36) as part of a pre-agreed trading plan, decreasing direct ownership by 0.96% to 79,228 units (SEC Form 4)
- Chief Executive Officer Van Kirk Richard Lee Jr sold $1,165,290 worth of shares (19,235 units at $60.58) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 79,993 units (SEC Form 4)
- Chief Financial Officer Charlton Alisha sold $140,983 worth of shares (2,300 units at $61.30), decreasing direct ownership by 10% to 21,870 units (SEC Form 4)
- Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Pro-Dex Inc.
- Pro-Dex, Inc. Announces Fiscal 2026 Fourth Quarter and Full-Year Results
- Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits